[
  {
    "ts": null,
    "headline": "Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?",
    "summary": "According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "url": "https://finnhub.io/api/news?id=eeae1b921f2adfea0c8a06a0c8f06cb44e0af23731540c0d6a3d5c849f9f0627",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768401002,
      "headline": "Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?",
      "id": 138113145,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
      "url": "https://finnhub.io/api/news?id=eeae1b921f2adfea0c8a06a0c8f06cb44e0af23731540c0d6a3d5c849f9f0627"
    }
  },
  {
    "ts": null,
    "headline": "PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock",
    "summary": "Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.",
    "url": "https://finnhub.io/api/news?id=f561be1dda255d356534a72334da790ad6b8f583336ccbaf7307d1e2ecf6aaca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768394700,
      "headline": "PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock",
      "id": 138111148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.",
      "url": "https://finnhub.io/api/news?id=f561be1dda255d356534a72334da790ad6b8f583336ccbaf7307d1e2ecf6aaca"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference",
    "summary": "Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the JPMorgan Healthcare Conference.",
    "url": "https://finnhub.io/api/news?id=d6f8d00d213e88039b110411652e19cc7093e8ec9df7d4de80999607d7c8eb25",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768392531,
      "headline": "Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference",
      "id": 138112555,
      "image": "https://image.cnbcfm.com/api/v1/image/108222573-17624550972025-11-06t184628z_1673660215_rc25rhas1dn5_rtrmadp_0_usa-trump.jpeg?v=1762455130&w=1920&h=1080",
      "related": "ABBV",
      "source": "CNBC",
      "summary": "Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the JPMorgan Healthcare Conference.",
      "url": "https://finnhub.io/api/news?id=d6f8d00d213e88039b110411652e19cc7093e8ec9df7d4de80999607d7c8eb25"
    }
  }
]